The company's high P/S ratio is backed by strong forecasted ...

The company's high P/S ratio is backed by strong forecasted revenue growth, outpacing the rest of the Pharmaceuticals industry. Investors anticipate this growth, justifying a higher stock price. A significant share price drop is unlikely under these conditions.